NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NERV stock has decreased by 41.7% and is now trading at $3.71. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences Inc (NASDAQ:NERV) announced its quarterly earnings data on Monday, May, 4th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.05. View Minerva Neurosciences' earnings history.

6 brokerages have issued 12 month target prices for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Minerva Neurosciences' stock price to reach $20.80 in the next twelve months. This suggests a possible upside of 460.6% from the stock's current price. View analysts' price targets for Minerva Neurosciences.

Headlines about NERV stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Minerva Neurosciences earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutMinerva Neurosciences.

Minerva Neurosciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,820,000 shares, a decline of 5.4% from the April 30th total of 2,980,000 shares. Based on an average trading volume of 392,500 shares, the short-interest ratio is presently 7.2 days. Currently, 9.0% of the company's shares are sold short. View Minerva Neurosciences' Current Options Chain.

Some companies that are related to Minerva Neurosciences include Passage Bio (IMRA), Frequency Therapeutics (FREQ), Athersys (ATHX), Aprea Therapeutics (APRE), Dynavax Technologies (DVAX), Trillium Therapeutics (TRIL), Passage Bio (KROS), Corbus Pharmaceuticals (CRBP), Crinetics Pharmaceuticals (CRNX), Basilea Pharmaceutica (BPMUF), Clovis Oncology (CLVS), AC Immune (ACIU), AnaptysBio (ANAB), Atreca (BCEL) and Viking Therapeutics (VKTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences.

NERV stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $3.71.

Minerva Neurosciences has a market capitalization of $145.51 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]